Program
MK-6194
A development code.
Its studies are mostly in Lupus Erythematosus, Systemic · Vitiligo · Colitis, Ulcerative · Dermatitis, Atopic, led by Merck.
Furthest: phase 2, since Oct 27, 20236 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 60 open or running | phase 2since Oct 27, 2023 | Feb 26, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 26, 2021First study: phase 1 study in Colitis, UlcerativeFirst studyNCT04924114 · 57 enrolled · United States, Georgia, Germany and more
- Jul 5, 2022Phase 1 study in Dermatitis, AtopicNCT05450198 · 72 enrolled · United States, Belgium, Bulgaria and more
- Oct 27, 2023Phase 2 study in Non-segmental VitiligoNCT06113328 · 169 enrolled · United States, Argentina, Australia and more
- Nov 29, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT06161116 · 149 enrolled · United States, Argentina, Brazil and more
- Oct 17, 2024Phase 1 study in HealthyNCT06649877 · 16 enrolled · United States
- Feb 10, 2025Phase 1 study in HealthyNCT06821334 · 37 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06821334Healthy · China | 1 | Completed | Aug 9, 2024 | 37 |
| NCT06649877Healthy · United States | 1 | Completed | Jul 13, 2023 | 16 |
| NCT06161116Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 2 | Terminated | Jul 30, 2025 | 149 |
| NCT06113328Non-segmental Vitiligo · United States, Argentina, Australia and more | 2 | Terminated | Mar 20, 2025 | 169 |
| NCT05450198Dermatitis, Atopic · United States, Belgium, Bulgaria and more | 1 | Completed | May 22, 2024 | 72 |
| NCT04924114Colitis, Ulcerative · United States, Georgia, Germany and more | 1 | Completed | Jan 8, 2024 | 57 |
How it is read
Names in the registry
- “MK-6194”, 6 entries
Codes read as this program: MK6194.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
- Vitiligo, 1 study
- Colitis, Ulcerative, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.